Ozempic typically begins to show its effects within the first few weeks after the initial injection, though it can vary from person to person
Zheng Y, Wang T, Tu X, et al
PIO, GLP-1R agonists, SGLT2 inhibitors and NAFLD: pathophysiological background PIO PIO, currently the only thiazolidinedione (TZD) in clinical practice, is a potent exogenous agonist of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-) and to a lesser extent, PPAR- [17, 44]
proposed that GLP-1 RAs might exert a direct effect on -cells, as the inhibition was not reversed by the insulin receptor antagonist or the SSTR2 antagonist [52]
Patients with peripheral artery disease, stroke, myocardial infarction, and heart failure who had depression showed an increased all-cause mortality
Glucagon, GLP-1 and Thermogenesis. Semaglutide weight loss: The New England Journal of Medicine (2021)